Sign In
Buy ALIM
$5.54
+0 (+0%)
At Close: Dec 12, 2024
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q4 2020 Results - Earnings Call Transcript
06:20pm, Saturday, 27'th Feb 2021
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q4 2020 Results - Earnings Call Transcript
Alimera Sciences Reports Fourth Quarter and 2020 Results
04:05pm, Wednesday, 24'th Feb 2021
Fourth Quarter Highlights:
Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both Indications
08:30am, Thursday, 18'th Feb 2021
ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmi
Alimera Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 and Provide Corporate Update
08:30am, Wednesday, 17'th Feb 2021
Conference Call to be held Thursday, February 25, 2021 at 9:00am Eastern Time Conference Call to be held Thursday, February 25, 2021 at 9:00am Eastern Time
Alimera Sciences to Present at the Microcap Rodeo Winter Wonderland Conference
08:30am, Monday, 15'th Feb 2021
ATLANTA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the managemen
Alimera Sciences, Inc. Discusses Its 2021 Global Expansion Strategy with The Stock Day Podcast
09:05am, Monday, 01'st Feb 2021
Phoenix, Arizona--(Newsfile Corp. - February 1, 2021) - The Stock Day Podcast welcomed Alimera Sciences, Inc. (NASDAQ: ALIM) ("the Company"), a pharmaceutical company that specializes in the commercia
Alimera Sciences Announces Preliminary Top-line Results for Fourth Quarter and Full-Year 2020
08:00am, Tuesday, 19'th Jan 2021
ATLANTA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription op
Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
08:00am, Tuesday, 05'th Jan 2021
ATLANTA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the managemen
Alimera Sciences Announces Launch of ILUVIEN® in the Netherlands
08:30am, Wednesday, 09'th Dec 2020
ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis Indications ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveiti
Alimera Sciences to Present at the 13th Annual LD Micro Main Event Virtual Conference
08:30am, Tuesday, 08'th Dec 2020
ATLANTA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the managemen
Alimera Sciences Announces Participation at the 11th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 17, 2020
08:00am, Monday, 16'th Nov 2020
ATLANTA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the managemen
Alimera Sciences Announces Third Quarter 2020 Financial Results
04:05pm, Wednesday, 28'th Oct 2020
Rebound Continues from COVID Challenges Rebound Continues from COVID Challenges
Trump's New Iran Sanctions Might Not Kill the Nuclear Deal, But They Will Hurt the U.N.
01:31pm, Wednesday, 19'th Aug 2020
Secretary of State Mike Pompeo is reportedly heading to New York to invoke 'snapback' provisions of the Iran nuclear deal. It's an act of diplomatic vandalism.
Alimera Sciences Signs Distribution Agreement With Nordic Prime to Expand International Sales of ILUVIEN® Into Nordic Countries
12:00pm, Thursday, 13'th Aug 2020
ATLANTA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmi
Up to 750,000 UK Covid test kits recalled due to safety concerns
11:11am, Saturday, 08'th Aug 2020
Products made by diagnostics firm Randox removed from care homes and individuals
